Information Provided By:
Fly News Breaks for July 11, 2019
Jul 11, 2019 | 11:38 EDT
Craig-Hallum analyst Alexander Nowak believes Tandem Diabetes (TNDM) and to a lesser extent Insulet (PODD) are the "clear beneficiaries" of the FDA recalling 189,000 Medtronic (MDT) 600-series pumps. The recall should further assist Tandem's share gains over the next several quarters and perhaps years, Nowak tells investors in a research note. And while UnitedHealth (UNH) has an exclusive contract with Medtronic Diabetes, the recall is further data Tandem can use to negotiate with UnitedHealth and argue for inclusion in its network, adds the analyst. He reiterates a Buy rating on shares of Tandem Diabetes with an $84 price target.